cro.directory
← Home
iXCells Biotechnologies logo

iXCells Biotechnologies

iPSC models, primary cells, and preclinical in vitro CRO services for drug discovery

Offers iPSC reprogramming, CRISPR genome editing, directed differentiation, and in vitro bioassay and ASO screening services. Builds human iPSC-derived cellular models for preclinical drug discovery.

Phases

Indications / Therapeutic Areas

Services

Modalities

About this organization

Overview

iXCells Biotechnologies describes itself as a preclinical drug discovery company focused on disease-relevant cellular models. Its website pairs a catalog of iPSCs, iPSC-derived cells, and primary cells with fee-for-service preclinical CRO services.

Preclinical CRO services

  • iPSC reprogramming of somatic cells into characterized iPSC lines using non-integrating methods
  • Cas9 genome editing, including isogenic disease models and precision target validation
  • Directed differentiation of iPSCs into neurons, cardiomyocytes, hepatocytes, and other cell types
  • Custom cell isolation tailored to tissue source, donor criteria, and application
  • In vitro bioassays, complex assay development, and antisense oligonucleotide (ASO) screening
  • Multi-cellular model building, 3D liver model signaling studies, and compound screening in iPSC-derived neurons and human immune cells

Scientific approach

The website states that the team includes PhD scientists and that the company offers patent-derived models intended to accelerate drug discovery and disease understanding. It also describes high-throughput iPSC screening platforms and an all-in-one iPSC platform (iPSCore) for generating human-relevant models.

Similar profiles by shared services, phases, and indications.

View all alternatives →See similar CROs ranked by shared capabilities

Submit a verified review for this organization.

Markdown mirror: /companies/ixcells-biotechnology.md